Format

Send to

Choose Destination
World J Gastroenterol. 2017 Nov 28;23(44):7813-7817. doi: 10.3748/wjg.v23.i44.7813.

Advances in endoscopic balloon therapy for weight loss and its limitations.

Author information

1
Department of Surgery, Texas Tech University, Odessa, TX 79763, United States. dvyas@sjgh.org.
2
Department Of Surgery, Michigan State University, Lansing, MI 48912, United States.
3
Department of Surgery, MetroWest Medical Center, Natick, MA 01760, United States.

Abstract

The field of medical and surgical weight loss is undergoing an explosion of new techniques and devices. A lot of these are geared towards endoscopic approaches rather than the conventional and more invasive laparoscopic or open approach. One such recent advance is the introduction of intrgastric balloons. In this article, we discuss the recently Food and Drug Administration approved following balloons for weight loss: the Orbera™ Intragastric Balloon System (Apollo Endosurgery Inc, Austin, TX, United States), the ReShape® Integrated Dual Balloon System (ReShape Medical, Inc., San Clemente, CA, United States), and the Obalon (Obalon® Therapeutics, Inc.). The individual features of each of these balloons, the method of introduction and removal, and the expected weight loss and possible complications are discussed. This review of the various balloons highlights the innovation in the field of weight loss.

KEYWORDS:

Endoscopic balloons; Gastric balloons; Obalon; Orbera; Reshape; Weight loss

PMID:
29209122
PMCID:
PMC5703910
DOI:
10.3748/wjg.v23.i44.7813
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center